Home > Result Summaries: Compounds > eltrombopag Result Summaries: eltrombopag GSKStudy ID Phase Title Summary (Download) 102860 phase 1 A Two-Part, Randomized, Placebo-Controlled Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Single, Oral Doses of the Thrombopoietin Receptor Agonist, Eltrombopag; and the Effect of Eltrombopag on Cardiac Repolarization as Compared to Placebo and Single Oral Doses of Moxiflo (0 citation(s)) 102861 phase 1 An Open-Label Mass Balance Study to Investigate the Metabolic Disposition of a Single Oral Dose of 14C SB-497115-GR in Healthy Male Subjects. (1 citation(s)) 102863 Phase 1 An open-label, randomized, five-period, period-balanced, crossover study to assess the effect of food and antacid on the pharmacokinetics of a single dose of SB-497115-GR (eltrombopag) in healthy volunteers (0 citation(s)) 104603 phase 1 : Phase I Study of SB-497115-GR – Single Oral Dose Study in Healthy Japanese Male Subjects – (0 citation(s)) 104631 phase 1 An open-label, randomized, five-period, period-balanced, crossover study to assess the effect of food and antacid on the pharmacokinetics of a single dose of SB-497115-GR (eltrombopag) in healthy volunteers (0 citation(s)) 105120 phase 1 An Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin when Co-administered with Eltrombopag (SB-497115-GR) in Healthy Adult Subjects (1 citation(s)) 105122 Phase 1 Phase I Bioequivalence Study for SB-497115-GR Phase II and Phase III Tablets (0 citation(s)) 105580 phase 1 Phase I Study of SB-497115-GR - Single and Multiple Oral Dose Study in Healthy Japanese Male Subjects - <Clinical Pharmacology Study> (1 citation(s)) 108109 phase 3 Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) -A Multicenter Study in Subjects with Chronic ITP Receiving a Double-Blind, Placebo-Controlled, Short-Term Treatment Followed by an Open-Label, Uncontrolled, Long-Term Treatment (1 citation(s)) 111433 phase 3 Clinical Evaluation of eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An extension study of eltrombopag in subjects, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study TRA108109 (NCT00540423)-<Phase III Study> (0 citation(s)) 111716 phase 1 A Phase I, Open-label, Single Sequence, Crossover Study Evaluating the Safety and the Pharmacokinetics of Lopinavir/Ritonavir and Eltrombopag Given Alone and when Co-administered in Healthy Adult Subjects. (1 citation(s)) 111718 phase 1 A randomized-open-label-five-period-balanced-crossover study to evaluate the relative bioavailability of an eltrombopag PfOS formulation relative to the 25 mg tablet formulation and to evaluate administration of the PfOS formulation with and separated 2 hours from a high calcium meal in HV (1 citation(s)) 111913 Phase 2 TPL111913, a Multi-centre, Open Label, Dose Ranging Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Eltrombopag in Japanese Thrombocytopenic Subjects with Chronic Liver Disease (0 citation(s)) 112509 phase 1 Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS) (1 citation(s)) 113918 phase 4 Cost Analysis of Thrombocytopenia Treatment in Patients with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (0 citation(s)) 113922 phase 4 Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim (0 citation(s)) 114013 n\a Systematic review of the clinical and cost effectiveness of treatments for idiopathic (immune) thrombocytopenic purpura (ITP): direct meta analysis (1 citation(s)) 114014 n\a Indirect Comparison of efficacy of treatments for idiopathic immune thrombocytopenic purpura - review of platelet responses and bleeding events (1 citation(s)) 114397 n\a Documentation of Factor V Leiden R506Q and prothrombin 20210G>A risk variants in chronic idiopathic thrombocytopaenic purpura (ITP) and chronic liver disease (CLD) patients experiencing thrombotic/thromboembolic events (TEE) during clinical studies with eltrombopag (0 citation(s)) 116010 phase 1 A Phase I, Open-label, Three-Period, Single Sequence, Crossover Study Evaluating the Drug-Drug Interaction Between Eltrombopag and Boceprevir and Between Eltrombopag and Telaprevir in Healthy Adult Subjects (0 citation(s)) 116344 n\a PGx471: Combined pharmacogenetic analysis of IL28B genotypes in TPL108390 and TPL103922 (0 citation(s)) 116684 n\a PGX6115: Genetic Effects on Different eltrombopag Exposure between Asians and Whites (0 citation(s)) 497115/003 phase 2 A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy (1 citation(s)) TPL102357 phase 2 A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre, Dose-Ranging, Parallel Group, Phase II Study to Assess Efficacy, Safety/Tolerability, and Pharmacokinetics of a Thrombopoietin Receptor Agonist, SB-497115-GR, when Administered as 30, 50, and 75 mg Once Daily for 12 weeks in Subjects with (1 citation(s)) TPL103922 phase 3 Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin (0 citation(s)) TPL104054 phase 3 Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures (1 citation(s)) TPL108390 phase 3 Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin) (0 citation(s)) TRA100773 phase 2 See Detailed Description (3 citation(s)) TRA100773_B phase 3 A double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral tablets once-daily for 6 weeks to adult male and (3 citation(s)) TRA102537 phase 3 A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic ITP. (4 citation(s)) TRA103452 phase 1 An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral dose of 50mg Eltrombopag in Healthy Subjects and in Volunteers with Mild, Moderate or Severe Hepatic Impairment (1 citation(s)) TRA104412 phase 1 An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50 mg [SB-497115] in Healthy Subjects and in Subjects with Mild, Moderate, or Severe Renal Impairment (1 citation(s)) TRA106914 phase 1 A phase I, double-blind, placebo and observer-blind positive controlled, randomized, parallel group study in healthy subjects to investigate the photoirritant potential of eltrombopag (1 citation(s)) TRA108057 phase 2 An Open-label repeat dosing study of eltrombopag olamine (SB-497115-GR) in adult subjects, with chronic idiopathic thrombocytopenic purpura (ITP) (3 citation(s)) TRC105499 phase 1 An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen (0 citation(s))
